αvβ3 Integrin and Fibroblast growth factor receptor 1 (FGFR1): Prognostic factors in a phase I-II clinical trial associating continuous administration of Tipifarnib with radiotherapy for patients with newly diagnosed glioblastoma

European Journal of Cancer

Volumn 49, Issue 9, 2013, Pages 2161-2169

  Ducassou, Anne ^a   Uro Coste, Emmanuelle ^b,c   Verrelle, Pierre ^d   Filleron, Thomas ^a   Benouaich Amiel, Alexandra ^a   Lubrano, Vincent ^b,c   Sol, Jean Christophe ^b,c   Delisle, Marie Bernadette ^b,c   Favre, Gilles ^c,e   Ken, Solea ^a   Laprie, Anne ^a,c   De Porre, Peter ^f   Toulas, Christine ^e   Poublanc, Muriel ^a   Cohen Jonathan Moyal, Elizabeth ^a,c,e  

^a INSTITUT CLAUDIUS REGAUD   (France)

^b CHU RANGUEIL   (France)

^c UNIVERSITÉ PAUL SABATIER   (France)

^d CENTRE JEAN PERRIN   (France)

^e CANCER RESEARCH CENTER OF TOULOUSE   (France)

^f JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Farnesyltransferase; FGFR1; Glioblastoma; ILK; Integrins; Phase II; Radiotherapy

Indexed keywords

FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 1; TIPIFARNIB; VITRONECTIN RECEPTOR;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CLINICAL ARTICLE; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; FEMALE; FIBROBLAST GROWTH FACTOR 2; FOCAL ADHESION KINASE 1; GLIOBLASTOMA; HUMANS; INTEGRIN ALPHAVBETA3; MALE; MIDDLE AGED; PROTEIN-SERINE-THREONINE KINASES; QUINOLONES; RADIATION-SENSITIZING AGENTS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RECEPTORS, VITRONECTIN; TREATMENT OUTCOME;

EID: 84877702029     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.02.033     Document Type: Article

References (33)

1. R. Stupp, W.P. Mason, and M.J. van den Bent Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 10 2005 987 996
2. I. Ader, C. Delmas, and J. Bonnet Inhibition of Rho pathways induces radiosensitization and oxygenation in human glioblastoma xenografts Oncogene 22 55 2003 8861 8869
3. C. Delmas, D. End, P. Rochaix, G. Favre, C. Toulas, and E. Cohen-Jonathan The farnesyltransferase inhibitor R115777 reduces hypoxia and matrix metalloproteinase 2 expression in human glioma xenograft Clin Cancer Res 9 16 Pt 1 2003 6062 6068
4. J. Milia, F. Teyssier, and F. Dalenc Farnesylated RhoB inhibits radiation-induced mitotic cell death and controls radiation-induced centrosome overduplication Cell Death Differ 12 5 2005 492 501
5. I. Ader, C. Toulas, and F. Dalenc RhoB controls the 24 kDa FGF-2-induced radioresistance in HeLa cells by preventing post-mitotic cell death Oncogene 21 39 2002 5998 6006
6. C. Delmas, C. Heliez, and E. Cohen-Jonathan Farnesyltransferase inhibitor, R115777, reverses the resistance of human glioma cell lines to ionizing radiation Int J Cancer 100 1 2002 43 48
7. S. Monferran, N. Skuli, and C. Delmas Alphavbeta3 and alphavbeta5 integrins control glioma cell response to ionising radiation through ILK and RhoB Int J Cancer 123 2 2008 357 364
8. N. Skuli, S. Monferran, and C. Delmas Activation of RhoB by hypoxia controls hypoxia-inducible factor-1alpha stabilization through glycogen synthase kinase-3 in U87 glioblastoma cells Cancer Res 66 1 2006 482 489
9. N. Skuli, S. Monferran, and C. Delmas Alphavbeta3/alphavbeta5 integrins-FAK-RhoB: a novel pathway for hypoxia regulation in glioblastoma Cancer Res 69 8 2009 3308 3316
10. E.C. Moyal, A. Laprie, and M. Delannes Phase I trial of tipifarnib (R115777) concurrent with radiotherapy in patients with glioblastoma multiforme Int J Radiat Oncol Biol Phys 68 5 2007 1396 1401
11. D.N. Louis, H. Ohgaki, and O.D. Wiestler The 2007 WHO classification of tumours of the central nervous system Acta Neuropathol 114 2 2007 97 109
12. A.A. Brandes, R. Stupp, and P. Hau EORTC study 26041-22041: phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma Eur J Cancer 46 2 2010 348 354
13. W. Remmele, and H.E. Stegner Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue Pathology 8 3 1987 138 140
14. M.E. Hegi, A.C. Diserens, and T. Gorlia MGMT gene silencing and benefit from temozolomide in glioblastoma N Engl J Med 352 10 2005 997 1003
15. M.E. Hegi, A.C. Diserens, and T. Gorlia MGMT gene silencing and benefit from temozolomide in glioblastoma N Engl J Med 352 10 2005 997 1003 2005/03/11 éd
16. Tensaouti F. Sysiphe-Neuroimaging software toolbox. Valencia./ES; 2008.
17. D.O. Dixon, and R. Simon Sample size considerations for studies comparing survival curves using historical controls J Clin Epidemiol 41 12 1988 1209 1213
18. P.L. Nghiemphu, P.Y. Wen, and K.R. Lamborn A phase I trial of tipifarnib with radiation therapy, with and without temozolomide, for patients with newly diagnosed glioblastoma Int J Radiat Oncol Biol Phys 81 5 2011 1422 1427
19. D.A. Haas-Kogan, A. Banerjee, and M. Kocak Phase I trial of tipifarnib in children with newly diagnosed intrinsic diffuse brainstem glioma Neuro Oncol 10 3 2008 341 347
20. A. Abdollahi, D.W. Griggs, and H. Zieher Inhibition of alpha(v)beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy Clin Cancer Res 11 17 2005 6270 6279
21. J.M. Albert, C. Cao, L. Geng, L. Leavitt, D.E. Hallahan, and B. Lu Integrin alpha v beta 3 antagonist Cilengitide enhances efficacy of radiotherapy in endothelial cell and non-small-cell lung cancer models Int J Radiat Oncol Biol Phys 65 5 2006 1536 1543
22. T. Mikkelsen, C. Brodie, and S. Finniss Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency Int J Cancer 124 11 2009 2719 2727
23. G. Gruber, J. Hess, and C. Stiefel Correlation between the tumoral expression of beta3-integrin and outcome in cervical cancer patients who had undergone radiotherapy Br J Cancer 92 1 2005 41 46
24. I.M. Bachmann, R.G. Ladstein, O. Straume, G.N. Naumov, and L.A. Akslen Tumor necrosis is associated with increased alphavbeta3 integrin expression and poor prognosis in nodular cutaneous melanomas BMC Cancer 8 2008 362
25. C. Massabeau, I. Rouquette, and V. Lauwers-Cances Basic fibroblast growth factor-2/beta3 integrin expression profile: signature of local progression after chemoradiotherapy for patients with locally advanced non-small-cell lung cancer Int J Radiat Oncol Biol Phys 75 3 2009 696 702
26. R. Stupp, M.E. Hegi, and B. Neyns Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma J Clin Oncol 28 16 2010 2712 2718
27. I. Ader, C. Muller, and J. Bonnet The radioprotective effect of the 24 kDa FGF-2 isoform in HeLa cells is related to an increased expression and activity of the DNA dependent protein kinase (DNA-PK) catalytic subunit Oncogene 21 42 2002 6471 6479
28. S. Fukui, H. Nawashiro, and N. Otani Nuclear accumulation of basic fibroblast growth factor in human astrocytic tumors Cancer 97 12 2003 3061 3067
29. M. Bredel, I.F. Pollack, J.W. Campbell, and R.L. Hamilton Basic fibroblast growth factor expression as a predictor of prognosis in pediatric high-grade gliomas Clin Cancer Res 3 11 1997 2157 2164
30. K. Sugiura, S. Ozawa, Y. Kitagawa, M. Ueda, and M. Kitajima Co-expression of aFGF and FGFR-1 is predictive of a poor prognosis in patients with esophageal squamous cell carcinoma Oncol Rep 17 3 2007 557 564
31. K. Gravdal, O.J. Halvorsen, S.A. Haukaas, and L.A. Akslen Expression of bFGF/FGFR-1 and vascular proliferation related to clinicopathologic features and tumor progress in localized prostate cancer Virchows Arch 448 1 2006 68 74
32. M. Volm, R. Koomagi, J. Mattern, and G. Stammler Prognostic value of basic fibroblast growth factor and its receptor (FGFR-1) in patients with non-small cell lung carcinomas Eur J Cancer 33 4 1997 691 693
33. E. Cohen-Jonathan Moyal, I. Ader, and C. Delmas Targeting FGFR-1 pathways by the antagonist SSR128129E overcomes the radioresistance of human glioma in vitro and in vivo Int J Radiat Oncol Biol Phys 75 3 2009 S70